We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Autologous Platelet Gel in Wound Healing of Coronary Artery Bypass Grafting (CABG) Patients

This study has been terminated.
(Study closed with no subjects accrued. PI decided to stop study.)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00672672
First Posted: May 6, 2008
Last Update Posted: August 3, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
University of Nebraska
May 2, 2008
May 6, 2008
August 3, 2011
February 2009
July 2012   (Final data collection date for primary outcome measure)
The surgical sites will be assessed for degree of healing and signs and symptoms of infection on postop days one and three and during the patients' follow up visits in the clinic. [ Time Frame: 30 days ]
Same as current
Complete list of historical versions of study NCT00672672 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Autologous Platelet Gel in Wound Healing of Coronary Artery Bypass Grafting (CABG) Patients
Autologous Platelet Gel in Wound Healing of Coronary Artery Bypass Grafting (CABG) Patients
The purpose of this study is to determine if the use of autologous platelet gel (APG) on sternal incision and conduit sites will improve wound healing and decrease the incidence of infection in patients undergoing coronary artery bypass grafting surgery
Not Provided
Interventional
Phase 3
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
  • Wounds
  • Infection
Biological: autologous platelet gel
Patients will receive APG to the surgical site in the operating room. The control site will receive no treatment.
Experimental: II
Patients who do not receive platlet gel.
Intervention: Biological: autologous platelet gel
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
250
Not Provided
July 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Any patient who meets criteria and consents to undergo a CABG procedure involving conduit sites and consents to this study.

Exclusion Criteria:

  • Any patient, after inclusion, whom is later determined to have had on-going therapy that could influence wound healing such as radiation or chemotherapy, extensive steroid use, or accidental trauma such as burns, etc.
Sexes Eligible for Study: All
19 Years to 90 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00672672
065-08
Yes
Not Provided
Not Provided
Ali Khoynezhad, MD, Univaersity of Nebraska Medical Center
University of Nebraska
Not Provided
Not Provided
University of Nebraska
August 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP